HGH Stock Overview
Heartland Group Holdings Limited provides various financial services in New Zealand and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Heartland Group Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$0.98 |
| 52 Week High | NZ$1.67 |
| 52 Week Low | NZ$0.98 |
| Beta | 0.97 |
| 1 Month Change | -10.45% |
| 3 Month Change | -26.49% |
| 1 Year Change | -33.22% |
| 3 Year Change | -41.54% |
| 5 Year Change | n/a |
| Change since IPO | -16.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| HGH | AU Banks | AU Market | |
|---|---|---|---|
| 7D | -5.7% | -2.4% | -2.2% |
| 1Y | -33.2% | 13.5% | 4.5% |
Return vs Industry: HGH underperformed the Australian Banks industry which returned 13.5% over the past year.
Return vs Market: HGH underperformed the Australian Market which returned 4.5% over the past year.
Price Volatility
| HGH volatility | |
|---|---|
| HGH Average Weekly Movement | 8.0% |
| Banks Industry Average Movement | 2.7% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: HGH's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine HGH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1875 | n/a | Jeff Greenslade | shareholders.heartland.co.nz |
Heartland Group Holdings Limited provides various financial services in New Zealand and Australia. The company offers savings accounts, term deposits, and direct and business call accounts. It also provides home loans, business loans, term loans, revolving credit, car loans, and reverse mortgage lending and other financial services.
Heartland Group Holdings Limited Fundamentals Summary
| HGH fundamental statistics | |
|---|---|
| Market cap | AU$829.50m |
| Earnings (TTM) | AU$77.94m |
| Revenue (TTM) | AU$228.54m |
10.3x
P/E Ratio0.9x
P/B RatioIs HGH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HGH income statement (TTM) | |
|---|---|
| Revenue | NZ$248.67m |
| Cost of Revenue | NZ$0 |
| Gross Profit | NZ$248.67m |
| Other Expenses | NZ$163.86m |
| Earnings | NZ$84.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 100.00% |
| Net Profit Margin | 34.10% |
| Debt/Equity Ratio | 258.7% |
How did HGH perform over the long term?
See historical performance and comparison